Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, ...
FierceBiotech1mon
Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
Seeking Alpha11d
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...
Seeking Alpha1mon
Biogen, Neomorph to collaborate on clinical candidates for Alzheimer's
Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...
Reuters1mon
Biogen lifts annual profit forecast as new treatments boost earnings
Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
Yahoo Finance1mon
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Last year, Biogen announced plans to cut 1,000 jobs — over 11% of its workforce — and reduce operating expenses by an additional $700 million by 2025. On Wednesday, the company projected that ...
AOL10d
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...